Olorinab (APD371), a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2, reduces colitis-induced acute and chronic visceral hypersensitivity in rodents

Abdominal pain is a key symptom of inflammatory bowel disease and irritable bowel syndrome, for which there are inadequate therapeutic options. We tested whether olorinab—a highly selective, full agonist of the cannabinoid receptor 2 (CB(2))—reduced visceral hypersensitivity in models of colitis and...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Joel, Garcia-Caraballo, Sonia, Maddern, Jessica, Schober, Gudrun, Lumsden, Amanda, Harrington, Andrea, Schmiel, Shirdi, Lindstrom, Beatriz, Adams, John, Brierley, Stuart M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675055/
https://www.ncbi.nlm.nih.gov/pubmed/33863856
http://dx.doi.org/10.1097/j.pain.0000000000002314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675055/
https://www.ncbi.nlm.nih.gov/pubmed/33863856
http://dx.doi.org/10.1097/j.pain.0000000000002314

Ejemplares similares